Aadi Bioscience Stock Price Drops 2.5%

Shares of the biotech company fall amid mid-day trading

Apr. 17, 2026 at 4:53am

Got story updates? Submit your updates here. ›

An extreme close-up photograph of metallic gears, levers, and mechanisms that make up the inner workings of a financial institution, conveying a sense of the industry's power and complexity.A close-up view of the complex machinery that powers the financial industry, reflecting the volatility and precision of the stock market.Redwood City Today

Aadi Bioscience, Inc. (NASDAQ:AADI), a clinical-stage biopharmaceutical company focused on developing precision medicines for genomically defined cancers, saw its stock price drop 2.5% during mid-day trading on Thursday. The company's shares traded as low as $3.74 before closing at $3.90, with approximately 316,496 shares changing hands, up 21% from the average daily volume.

Why it matters

Aadi Bioscience's stock performance is closely watched by investors and analysts as the company continues to develop its lead product candidate, fimepinostat, a novel dual inhibitor of histone deacetylase (HDAC) and phosphatidylinositol 3-kinase (PI3K). The company's research strategy focuses on identifying molecular drivers of tumor growth and designing small-molecule inhibitors to target these pathways.

The details

The stock has a 50-day simple moving average of $3.37 and a two-hundred day simple moving average of $2.74. The firm has a market cap of $96.32 million, a PE ratio of -1.71 and a beta of 0.68.

  • Aadi Bioscience's stock price dropped 2.5% during mid-day trading on Thursday, April 17, 2026.

The players

Aadi Bioscience, Inc.

A clinical-stage biopharmaceutical company focused on developing precision medicines for genomically defined cancers. Headquartered in Redwood City, California, Aadi Bioscience was founded in 2012 and went public in 2019 on the Nasdaq Stock Market under the ticker AADI.

Got photos? Submit your photos here. ›

The takeaway

Aadi Bioscience's stock price fluctuations are closely monitored by investors as the company continues to develop its lead product candidate, fimepinostat, which targets key molecular drivers of tumor growth. The company's research strategy and pipeline progress will be crucial factors in determining its future stock performance.